Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (noted as Ocugen, Inc. in metadata) covers the special meeting of stockholders held on November 22, 2016. The filing reports on the submission of matters to a vote of security holders, specifically regarding a significant equity issuance.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on corporate governance and capital structure changes.
Material Changes
The primary material change reported is the stockholder approval of the issuance of up to 24,203,942 shares of common stock. This issuance consists of:
- 10,737,275 shares issuable upon conversion of Series A Convertible Preferred Stock.
- 13,466,667 shares issuable upon the exercise of certain warrants.
This transaction was required to be approved by stockholders under NASDAQ Marketplace Rule 5635(d) due to the volume of shares involved relative to the outstanding stock.
Voting Results and Management Commentary
Management submitted the proposal to satisfy NASDAQ listing requirements. The voting results were as follows:
- Quorum: 11,898,562 shares (approximately 75.0% of entitled shares) were represented at the meeting.
- Proposal 1 Approval: The NASDAQ Proposal was approved.
- Votes For: 10,347,424
- Votes Against: 19,650
- Broker Non-Votes: 0
The filing references a definitive proxy statement on Schedule 14A filed on November 2, 2016, for further details on the proposals.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on November 2, 2016, for full details on the Series A Preferred Stock and warrant terms.
- Confirm the post-transaction share count and dilution impact on existing shareholders.
- Review the Securities Purchase Agreement dated September 15, 2016, regarding the Series A Preferred Stock.
- Check subsequent filings for the actual conversion of preferred stock and exercise of warrants.